Key result
Renin inhibitors have faced slow development due to synthesis costs and bioavailability issues, but they still show substantial therapeutic promise.
Design
Review
Authors
Loading...
Renin inhibitors should not yet influence RAS inhibitor selection; leaves open their potential with improved formulations.
Despite historical setbacks related to cost and bioavailability, renin inhibitors may still hold therapeutic potential.
Fisher et al. (2001) conducted a review in Renin-angiotensin system modulation. Renin inhibitors vs. AngII antagonists was evaluated. Renin inhibitors have faced slow development due to synthesis costs and bioavailability issues, but they still show substantial therapeutic promise.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: